{"id":"W2963065632","doi":"10.1016/j.euo.2019.06.018","title":"Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?","year":2019,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"Meso Scale Diagnostics; Novartis Pharma; F. Hoffmann-La Roche; Roche; GlaxoSmithKline; AstraZeneca; Ipsen; Bayer Schering; Novartis; Pfizer; Bristol-Myers Squibb","keywords":"Temsirolimus; Sunitinib; Medicine; Everolimus; Internal medicine; Renal cell carcinoma; Oncology; Discovery and development of mTOR inhibitors; Refractory (planetary science); Pazopanib; Sorafenib; Tyrosine-kinase inhibitor; Progressive disease; Cancer; Progression-free survival; Urology; PI3K/AKT/mTOR pathway; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002491212,0.0008245155,0.003702861,0.001294525,0.001872351,0.005052859,0.001585945,0.006884905,0.009182985],"category_scores_gemma":[0.006193348,0.0004148963,0.002831885,0.0009505787,0.001484974,0.009010259,0.001109866,0.006981754,0.003119813],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002500735,"about_ca_system_score_gemma":0.009027788,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006669623,"about_ca_topic_score_gemma":0.02386316,"domain_scores_codex":[0.998673,0.0003872389,0.0002549223,0.000165144,0.0002346233,0.0002851669],"domain_scores_gemma":[0.9956796,0.001419476,0.0004690506,0.00008979134,0.001081221,0.001260898],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"case_report","study_design_scores_codex":[0.002043246,0.001094709,0.02403375,0.004792752,0.0008877967,0.006503628,0.0003442349,0.001521655,0.001287935,0.006242104,0.3238396,0.6274086],"study_design_scores_gemma":[0.001461022,0.002023874,0.04440105,0.02145029,0.002291407,0.02539701,0.01069365,0.002809036,0.0008997998,0.0325796,0.8552719,0.0007212104],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.01458674,0.5086874,0.002804777,0.4345266,0.01779656,0.0003203105,0.0007038685,0.000314584,0.02025932],"genre_scores_gemma":[0.1593251,0.5439844,0.01183516,0.1885176,0.07693471,0.0007259006,0.002425842,0.0001585696,0.01609273],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.009182985,"threshold_uncertainty_score":0.03072017,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03048655956001292,"score_gpt":0.2902919945344529,"score_spread":0.25980543497444,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}